Malignant Histiocytic and Dendritic Cell Neoplasm

Malignant Histiocytic and Dendritic Cell Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

82 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 43
Recruiting: 21
Ph III recruiting: 1
Growth YoY: —
Industry share: 14%
Top sponsor: Fred Hutchinson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06006403	Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm	completed	Phase 1 / Phase 2	5	Chongqing Precision Biotech Co., LtdINDUSTRY	1	Aug 5, 2026	clinicaltrials
NCT03485547	Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)	completed	Phase 1	5	Dana-Farber Cancer InstituteOTHER	1	Feb 2, 2026